Trial Profile
Efficacy and safety of Vemurafenib in patients with Hairy Cell Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 03 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.